You are here

Home » Content

ORTA DERECEDE KRONİK BÖBREK YETERSİZLİĞİ OLAN HASTALARDA ANJİOTENSİN DÖNÜŞTÜRÜCÜ ENZİM İNHİBİTÖRLERİ İLE ANGİOTENSİN RESEPTÖR ANTAGONİSTLERİNİN KARŞILAŞTIRILMASI

THE COMPARISON OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR ANTAGONISTS IN PATIENTS WITH MODERATE CHRONIC RENAL FAILURE

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In this prospective-randomised study, the effects of angiotensin converting enzyme inhibitors (enaiapril) and angiotensin receptor antagonists (losartan) use on various laboratory parameters in 27 patients with moderate chronic renal failure were compared regarding safety and efficacy of both. The follow-up time was 6 month. Thirteen patients (M/F:3/10, mean age:41 ± 15 years) for enaiapril and 14 patients (M/F:4/10, mean age:5J±13 years) for losartan were included. There was no difference for age, gender and primary renal disease between two groups. More significant decrease in systolic blood pressure was observed in enaiapril group (from 142±21 mmHg to 133±23 mmHg, p<0.001) than losartan group (from 153±13 mmHg to 139±13 mmHg, p<0.05). No significant change after treatment was found between study groups. Serum K levels were significantly increased after treatment in enaiapril group (from 4,7±0,6 to 5,4±0,5 mmHg, p<0.05), but no significant change in losartan group was observed. Serum uric-acid levels were significantly decreased (from 6.2 ± 1,8 to 5.8 ± 1.6, p=0.01) in losartan group, but no change in enaiapril group was found. In conclusion, better blood pressure control could be obtained with enaiapril compared to losartan in this group of patients. Deterioration in renal function in both groups were similar. However, serum potassium levels elevated more in the enaiapril group than losartan. Decrease in serum uric acid levels after losartan may be a superiority compare to enaiapril treatment.
Bookmark/Search this post with
Abstract (Original Language): 
Buprospektif-randomize çalışmada, orta derecede kronik böbrek yetersizliği olan 27 hastada anjiotensin dönüştürücü enzim inhibitörleri (enaiapril) ve anjiotensin reseptör antagonistlerinin (losartan) çeşitli laboratuar parametreleri üzerine olan etkileri açısından güvenilirlik ve etkinliği karşılaştınlmıştır. İzleme süresi 6 aydı. Enaiapril kullanan 13 (E/K: 3/10, ortalama yaş: 4!±J5) ve losartan kullanan 14 (E/K: 4/10, ortalama yaş: 51±13) hasta çalışmaya alındı. İki grup arasında yaş, cinsiyet ve primer renal hastalık açısından bir fark yoktu. Enaiapril grubunda (142+21 mmHg'dan 133+23 mmtig'ya, p<0.001) sistolik kan basıncında losartan grubuna (15 3 ±13 mmHgdan 139 ±13 mmHg'ya, p<0.05) göre daha anlamlı düşme saptandı. Enaiapril grubunda serum potasyum düzeyleri tedavi sonrası anlamlı olarak artarken (4.7±0.6 inEq/L'den 5.4±0.5 mEg/L'ye, p<0.05), losartan grubunda anlamlı bir değişiklik gözlenmedi. Serum ürik asit düzeyleri de losartan grubunda anlamlı olarak azalırken (6.2±1.8 mg/dlden, 5.8±1.6 mg/dl'ye, p=0.01), enaiapril grubunda değişiklik görülmedi. Sonuç olarak, losartanla karşdaştırıldığında enaiapril ile daha iyi kan basıncı kontrolü elde edilebilir. Renal fonksiyondaki bozulma her iki grupta da benzerdi. Ancak, serum potasyum düzeyleri enaiapril grubunda losartan grubuna göre daha fazla yükselmiştir. Losartan tedavisi sonrası serum ürik asit düzeylerindeki azalma enaiapril tedavisine göre bir üstünlük olarak kabul edilebilir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_343.pdf
  • 3
153-157
  • Turkish

REFERENCES

References: 

1. Klahr S, Levey S, Beck GJ, et al. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-884.
2. Anderson
S
, Jung FF, lngelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.
3. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T: Angiotensin Blokade and the progression of renal damage in the spontaneously hypertensive rates.
Hypertension 1993, 21:975-979.
4. Pollock DM, DivishBJ, Polakowski JS, Opgenorth TJ:
Angiotensin II receptor blokade improves renal function in rates with reduced renal mass. Pharmacol
Exp Ther 1993, 267:657-663.
5. Gansevoort RT, De Zeeuw D, De Jong P, Is the antiproteinuric effect of ACE inhibitation mediated by interference in the renin-angiotensin system; Kidney Int 1994,4S:861-867.
6. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit
D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension 1998 Feb;31(2):684-91.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearence from serum creatinine. Nephron 1975; 16:31.
8.
Altıntep
e L. İ.Ü. İstanbul Tıp Fakültesi, İç Hastalıkları AB.D. (Uzmanlık Tezi), İmmunosupressif tedaviye dirençli nefrotik sendromlu hastalarda losartan ve enalapril tedavilerinin karşılaştırılması. 1998.
9. Tannen RL. Disorders of potassium balance. In: Brenner BM, Rector FC, eds. The kidney. 6th ed.
Philadelphia, Pa: WB Saunders Co 1998;999-1037.
10. Nakashima M, Uematsu T, Kosuge K, Kanamura M, Pilot study of the uricosuric effect of Dup 753, a new angiotensin II receptor antagonist, in healthy subjects.
Eur J Clin Pharmacol 1992, 42:333-335.
11. Mallion JM, Bradstreet DC, Makris L, Goldberg Al, Halasz S, Sweet CS, Lim NY, Madonna O. Antihypertensive efficacy and tolerability of daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J
Hypertens 1995; 13:S35-S41.
12. Eschbach JW, Hematologic consequences of renal failure. In: Brenner BM, Rector FC, eds. The kidney.
4th ed. Philadelphia, WB Saunders Co 1991 ;pp:2019-2035.
13. Navarro JF, Garcia J, Macia M, Mora C, Chahin J,
Gallego E, Mendez ML, del Castillo N. Effects of
losartan on the treatment of posttransplant
erythrocytosis. Clin Nephrol 1998 Jun;49(6):370-2.
14. Ok E, Akçiçek F, Toz H et al. Comparison of the effect of enalapril and theophylline on polycytemia after renal tranplantation, Transplantation 1995; 15:59(11): 1623¬6.
15. Suhan BA, Brently RR, Borher CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lower hematocrit in posttransplant erithrocytosis. J Am Soc
Nephrol 1998; 9(6): 1104-8.
16. Matsumura M, Nomura H, Koni 1, Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group.Nephron 1997;77(2): 164-8.
17. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes.
Lancet 1998 Jul 25;352(9124):286.
18. Lamb RV, Walton T. Acute renal failure after administration of losartan. Letter. W V Med J 1996
Sep-Oct;92(5):241.
19. Ostermann M, Goldsmith DJ, Doyle T, Kingswood JC, Sharpstone P. Reversible acute renal failure induced by losartan in a renal transplant recipient. Postgrad Med J
1997 Feb;73(856): 105-7.

Thank you for copying data from http://www.arastirmax.com